Leerink Swann set a $46.00 price target on Zai Lab (NASDAQ:ZLAB) in a research report report published on Tuesday, TipRanks reports. The brokerage currently has a buy rating on the stock.

Several other equities analysts also recently weighed in on the company. BidaskClub raised Zai Lab from a sell rating to a hold rating in a research report on Wednesday, June 5th. Zacks Investment Research raised Zai Lab from a hold rating to a buy rating and set a $30.00 target price for the company in a research report on Saturday, May 11th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Zai Lab has an average rating of Buy and an average price target of $36.90.

NASDAQ ZLAB opened at $29.71 on Tuesday. The stock has a market capitalization of $1.65 billion, a price-to-earnings ratio of -11.25 and a beta of 0.96. Zai Lab has a 1-year low of $14.29 and a 1-year high of $33.86.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Citigroup Inc. acquired a new position in shares of Zai Lab during the first quarter worth about $40,000. Barclays PLC acquired a new position in shares of Zai Lab during the fourth quarter worth about $65,000. Bank of America Corp DE grew its position in shares of Zai Lab by 20.3% during the fourth quarter. Bank of America Corp DE now owns 6,528 shares of the company’s stock worth $151,000 after buying an additional 1,103 shares in the last quarter. Bank of Montreal Can grew its position in shares of Zai Lab by 18.5% during the fourth quarter. Bank of Montreal Can now owns 9,692 shares of the company’s stock worth $225,000 after buying an additional 1,512 shares in the last quarter. Finally, Matthews International Capital Management LLC acquired a new position in shares of Zai Lab during the fourth quarter worth about $270,000. 36.39% of the stock is owned by institutional investors.

Zai Lab Company Profile

Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC.

Featured Article: QQQ ETF

Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.